Circulating (CD3−CD19+CD20−IgD−CD27highCD38high) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?
Joint Authors
Nortier, Joëlle L.
Beukinga, Ingrid
Gu-Trantien, Chunyan
Willard-Gallo, Karen
Pradier, Olivier
Pozdzik, Agnieszka
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-07-14
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Membranous nephropathy (MN) is a kidney specific autoimmune disease mainly mediated by anti-phospholipase A2 receptor 1 autoantibody (PLA2R1 Ab).
The adequate assessment of chimeric anti-CD20 monoclonal antibody, rituximab (RTX), efficacy is still needed to improve clinical outcome of patient with MN.
We evaluated the modification of plasmablasts (CD3−CD19+CD20−IgD− C D 27 h i g h C D 38 h i g h ), a useful biomarker of RTX response in other autoimmune diseases, and memory (CD3−CD19+CD20+IgD−CD27+CD38−) and naive (CD3−CD19+CD20+IgD+CD27− C D 38 l o w ) B cells by fluorescence-activated cell sorter analysis in PLA2R1 related MN in one patient during the 4 years of follow-up after RTX.
RTX induced complete disappearance of CD19+ B cells, plasmablasts, and memory B cells as soon as day 15.
Despite severe CD19+ lymphopenia, plasmablasts and memory B cells reemerged early before naive B cells (days 45, 90, and 120, resp.).
During the follow-up, plasmablasts decreased more rapidly than memory B cells but still remained elevated as compared to day 0 of RTX.
Concomitantly, anti-PLA2R1 Ab increased progressively.
Our single case report suggests that, besides monitoring of serum anti-PLA2R1 Ab level, enumeration of circulating plasmablasts and memory B cells represents an attractive and complementary tool to assess immunological activity and efficacy of RTX induced B cells depletion in anti-PLA2R1 Ab related MN.
American Psychological Association (APA)
Pozdzik, Agnieszka& Beukinga, Ingrid& Gu-Trantien, Chunyan& Willard-Gallo, Karen& Nortier, Joëlle L.& Pradier, Olivier. 2016. Circulating (CD3−CD19+CD20−IgD−CD27highCD38high) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?. Mediators of Inflammation،Vol. 2016, no. 2016, pp.1-10.
https://search.emarefa.net/detail/BIM-1111218
Modern Language Association (MLA)
Pozdzik, Agnieszka…[et al.]. Circulating (CD3−CD19+CD20−IgD−CD27highCD38high) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?. Mediators of Inflammation No. 2016 (2016), pp.1-10.
https://search.emarefa.net/detail/BIM-1111218
American Medical Association (AMA)
Pozdzik, Agnieszka& Beukinga, Ingrid& Gu-Trantien, Chunyan& Willard-Gallo, Karen& Nortier, Joëlle L.& Pradier, Olivier. Circulating (CD3−CD19+CD20−IgD−CD27highCD38high) Plasmablasts: A Promising Cellular Biomarker for Immune Activity for Anti-PLA2R1 Related Membranous Nephropathy?. Mediators of Inflammation. 2016. Vol. 2016, no. 2016, pp.1-10.
https://search.emarefa.net/detail/BIM-1111218
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1111218